Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

GS-930: Began a Phase I study of the pro-drug GS-930 in 30 HIV-infected patient

WIR Staff
February 12, 1996 8:00 AM UTC

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS-930, pro-drug of cidofovir Indication: Cytomegalovirus (CMV) retinitis in AIDS Status: Began a Phase I study of the pro-drug GS-930 in 30 H...